Login to Your Account



Rigel Tumbles on Phase II RA Failure; Lilly Drug Misses, Too

By Catherine Shaffer
Staff Writer

Friday, December 14, 2012

AstraZeneca plc's top-line results from a Phase IIb study of fostamatinib in rheumatoid arthritis (RA) showed that the drug was superior to placebo at six weeks, but it fell short of a secondary goal of noninferiority against Humira (adalimumab, Abbott), sending shares of partner Rigel Pharmaceuticals Inc., of South San Francisco, plunging by almost 35 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription